The “war” on cancer: are we “winning” or “losing” or what?

Clifton Leaf is a cancer survivor. He is also the Editor-in-Chief of Fortune magazine. And he has long argued that we may not be making the most astute decisions about how we are trying to find “the best” and “the rightest” ways to diagnose, treat, and manage cancer. … READ MORE …

Preliminary data from the TRITON 2 trial of rucaparib in mCRPC

A poster presented at the ESMO meeting in Munich has just reported data from an unplanned, preliminary analysis of data from the first 85 patients (out of a scheduled total of 150 patients) enrolled in the TRITON 2 trial of the PARP inhibitor rucaparib (Rubraca) … READ MORE …

New data shows that local prostate radiotherapy improves OS in some men with newly diagnosed, metastatic prostate cancer

New data from the ongoing STAMPEDE trial in the UK and Switzerland has now confirmed that ablative radiation of the prostate itself (debulking of the primary tumor) improves overall survival (OS) in men newly diagnosed with metastatic prostate cancer who have a low metastatic disease burden but not in those with higher burden of disease. … READ MORE …

Using low-dose abiraterone acetate with food (or a standard dose with no food)

We have known for some time that abiraterone acetate 250 mg, when given with food, appears to have activity that may — in at least some patients — be comparable to the activity of abiraterone acetate 1,000 mg given without food. … READ MORE …

Examining “value” in the management of prostate cancer

Three new articles in the Journal of Oncology Practice take close look at the issue of risk/benefit and “value” in the management of prostate cancer today — and the management of advanced disease in particular. … READ MORE …

Effects of prazosin + radiation therapy on recurrence-free survival

The following was brought to our attention by Arthur as a consequence of a question posed on Ask Arthur by a reader within the past 24 hours. … READ MORE …

Low-dose-rate brachytherapy monotherapy at the Mayo Clinic

A clinical research team from the Mayo Clinic (Routman et al.) has reported 10-year oncological results on 974 consecutive low- and intermediate-risk patients treated with low-dose-rate brachytherapy monotherapy (using iodine-125 seeds) from 1998 to 2013. … READ MORE …